Organization
Hutchison Medipharma
21 clinical trials
Clinical trial
A Phase 3, Randomized, Open-label, Multi-center Study to Evaluate the Efficacy and Safety of Surufatinib Plus Toripalimab Versus FOLFIRI as a Secondline Treatment in Patients With Advanced Neuroendocrine CarcinomaStatus: Recruiting, Estimated PCD: 2025-05-31
Clinical trial
An Open-Label, Phase 1b/2 Study to Evaluate the Safety and Efficacy of Fruquintinib in Combination With Tislelizumab in Patients With Advanced Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2024-07-01
Clinical trial
An Open-Label Study of Surufatinib in Japanese Patients With Neuroendocrine TumorsStatus: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
A Phase II/III Clinical Study to Evaluate the Efficacy and Safety of Fruquintinib in Combination With Sintilimab Versus Axitinib or Everolimus as Second-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma (FRUSICA-2)Status: Recruiting, Estimated PCD: 2024-11-01
Clinical trial
A Multi-Center, Open-Label, Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Surufatinib (HMPL-012), Previously Named Sulfatinib in Advanced Solid TumorsStatus: Completed, Estimated PCD: 2023-04-25
Clinical trial
A Phase 1 Open-Label Study to Assess the Safety, Pharmacokinetics and Preliminary Efficacy of HMPL-689 in Patients With Lymphomas Failed of Standard of Care or No Standard of Care ExistedStatus: Completed, Estimated PCD: 2023-08-02
Clinical trial
A Phase I Monocentric, Open-label, Randomized, Crossover Clinical Study to Evaluate the Pharmacokinetics and Bioequivalence of HMPL-523 Tablets Produced by Two Different Manufacturers in Healthy Chinese SubjectsStatus: Completed, Estimated PCD: 2022-07-31
Clinical trial
A Randomized, Double-blind, Multi-center Phase III Clinical Study to Assess the Efficacy and Safety of Surufatinib Compared to Placebo in Patients With Advanced Pancreatic Neuroendocrine TumorsStatus: Completed, Estimated PCD: 2019-11-11
Clinical trial
Clinical Study to Evaluate the Efficacy, Safety and Tolerability of Savolitinib + Osimertinib Versus Pemetrexed + Platinum in Treatment of Patients With NSCLC With MET AmplificationStatus: Recruiting, Estimated PCD: 2024-09-15
Clinical trial
A Multi-center, Open-label, Phase II Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of Savolitinib in Treating Gastric Cancer and Esophagogastric Junction Adenocarcinoma Patients With MET Gene AmplificationsStatus: Recruiting, Estimated PCD: 2025-04-01
Clinical trial
Study Title A Multicenter, Open-label, Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMPL-295S1 in Treatment of the Patients With Advanced Malignant Solid TumorsStatus: Recruiting, Estimated PCD: 2023-09-01
Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HMPL-523 in Treatment of Primary Immune Thrombocytopenia (ITP) in Adults(ESLIM-01 Study)Status: Active (not recruiting), Estimated PCD: 2023-12-30
Clinical trial
A Multicenter, Randomized, Double-blind, Phase III Clinical Study to Evaluate the Efficacy and Safety of Savolitinib + Osimertinib Versus Placebo + Osimertinib as the First Line Therapy for Patients With EGFRm+/MET+ NSCLCStatus: Recruiting, Estimated PCD: 2024-11-15
Clinical trial
A Multicenter, Open-label, Phase I Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of HMPL-760 in Patients With Relapsed/Refractory B-Cell Non-Hodgkin's LymphomaStatus: Recruiting, Estimated PCD: 2024-07-01
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Phase II/III Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of HMPL-523 in the Treatment of Warm Antibody Autoimmune Hemolytic AnemiaStatus: Active (not recruiting), Estimated PCD: 2026-09-01
Clinical trial
A Multicenter, Open-label, Phase II Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Tazemetostat for the Treatment of Patients With Relapsed/Refractory Follicular LymphomaStatus: Recruiting, Estimated PCD: 2023-06-01
Clinical trial
An Open-Label, Multi-Center Phase II Study of Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Patients With Extensive-Stage Small Cell Lung CancerStatus: Recruiting, Estimated PCD: 2024-04-01
Clinical trial
A Phase 1 Study To Assess The Effect Of Moderate Renal Impairment On The Pharmacokinetics Of SurufatinibStatus: Completed, Estimated PCD: 2021-08-21
Clinical trial
A Randomized, Double-blind, Multi-center Phase III Clinical Study to Assess the Efficacy and Safety of Surufatinib Compared to Placebo in Patients With Advanced Extrapancreatic Neuroendocrine TumorsStatus: Completed, Estimated PCD: 2019-03-31
Clinical trial
A Phase II, Open-label, Single-arm, Multi-center Study of the Efficacy and Safety of Surufatinib Single Agent or Surufatinib Combined With Toripalimab in Patients With Advanced Solid TumorsStatus: Completed, Estimated PCD: 2023-02-28
Clinical trial
A Global Multicenter Randomized Placebo-Controlled Phase 3 Trial To Compare The Efficacy And Safety Of Fruquintinib Plus Best Supportive Care To Placebo Plus Best Supportive Care In Patients With Refractory Metastatic Colorectal CancerStatus: Active (not recruiting), Estimated PCD: 2022-07-29